Document is current

Article History

Received: 24 January 2025

Accepted: 13 June 2025

First Online: 15 July 2025

Declarations

:

: All animals used in the study were housed in a pathogen-free environment at the animal facility of the Institute for Research in Immunology and Cancer (IRIC) and maintained in accordance with the guidelines approved by the Animal Care Committee of Université de Montréal. The ethics protocol entitled Development of new therapies for modulation of the immune system (Protocol #22-065) was approved in September 2024 by the “comité de déontologie de l’experientation animale” of Université de Montréal. RoosterBio confirms that the human bone marrow aspirates used for the production of RoosterBio’s research use only RoosterVial™ products as well as RoosterVial™ products produced for further manufacturing under current good manufacturing practices are ethically sourced from consenting donors. RoosterBio sources commercially available in vitro research use only as well as clinical grade human bone marrow aspirate from qualified proprietary vendors. All human bone marrow aspirate collections are from healthy adult consented donors. Collection protocols and the donor-informed consent documents are approved by an Institutional Review Board (IRB).

: Not applicable.

: Daniela Stanga and Marina P. Gonçalves were employees of Defence Therapeutics Inc. at the time of the study and declare competing financial interest. All remaining authors declare no competing interests.

: The authors declare that they have not use AI-generated work in this manuscript.